Inhibition of FGFR3 and treatment of multiple myeloma
US7825132B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2004 |
| Grant date | Nov 2, 2010 |
| Priority date | — |
| Expiry date | Nov 3, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/496
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.